Business Context and Reporting Period
This Form 8-K Current Report was filed by Processa Pharmaceuticals, Inc. on August 8, 2023. The filing primarily addresses significant changes in executive leadership, specifically the appointment of a new Chief Executive Officer and the departure of the Chief Operating Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- Appointment of CEO: Mr. George Ng was appointed as Chief Executive Officer and a director effective August 8, 2023.
- Departure of COO: Mr. R. Michael Floyd resigned as Chief Operating Officer by mutual agreement, effective August 31, 2023.
- Role Continuity: Dr. David Young will continue serving as a Board member and President of Research and Development.
Compensation and Outlook
Mr. Ng's employment agreement includes the following compensation terms:
- Base Salary: $400,000 annually.
- Bonus: Eligible for up to $100,000 contingent on meeting performance milestones in 2023 and 2024.
- Equity Awards: Granted 800,000 Restricted Stock Units (RSUs).
- 400,000 RSUs vest ratably over three years.
- 400,000 RSUs are performance-based, vesting upon the raising of gross proceeds: 200,000 units upon raising $10,000,000 and an additional 200,000 units upon raising another $10,000,000.
The filing includes a Safe Harbor Statement noting that forward-looking statements regarding Mr. Ng's service and start date are subject to risks and uncertainties detailed in the Company's 2022 Form 10-K and 2023 Form 10-Q.
Investor Verification Checklist
- Verify the terms of the Employment Agreement (Exhibit 10.1) for specific performance metrics tied to the bonus and RSU vesting.
- Review the Company's recent 10-K and 10-Q filings to assess current liquidity, as the performance-based equity vesting is contingent on raising $20,000,000 in gross proceeds.
- Confirm the transition plan for the Chief Operating Officer role following Mr. Floyd's resignation on August 31, 2023.
- Check for any subsequent filings regarding the status of the fundraising targets required for Mr. Ng's equity vesting.